When the industry says plasma donation is safe, ask: safe from what? Most of the reassurance is about the moment in the chair — a passing reaction, an infection, a fainting spell. That's a real question, and the short answer is that those acute events are uncommon.
But there's a second, quieter question the centers rarely raise: what happens to the biomarkers your body depends on — total serum protein, immunoglobulin G (IgG), ferritin — when you hand over plasma twice a week, month after month? That's what the studies below actually measure. The picture isn't "nothing happens." It's "measurable things change, they get bigger with frequency, and they take longer to recover than a center visit."
The 2024 randomized trial: the clearest evidence we have
The strongest single study is a non-inferiority randomized controlled trial, published in the journal Vox Sanguinis, that took 120 male blood donors and split them into three groups: high-frequency plasma donors (three 650 mL donations every two weeks), regular-frequency donors (one 650 mL donation every two weeks), and a control group giving whole blood every three months.
The findings were unambiguous. Compared with controls, high-frequency donors had lower total serum protein (a mean difference of -5.5 g/L, 95% CI -7.4 to -3.6) and lower IgG (-2.8 g/L, 95% CI -3.8 to -1.8). Within groups, the trial recorded significant reductions — increasing in size with donation frequency — across total protein, IgG and its subclasses, IgM, IgA, ferritin, and hemoglobin. Crucially, many of these biomarkers took more than four weeks to return to baseline.
Only mild adverse events were reported, and donation frequency had no effect on psychological distress. So this isn't a study of people collapsing in chairs. It's a study of chemistry drifting in a direction that scales with how often you donate. The authors concluded that high- and regular-frequency plasmapheresis substantially reduces these concentrations, with greater reductions at higher frequency — and that further research is needed on the long-term health implications.
The 45-liter line: the safety ceiling vs. the legal ceiling
The reassuring number you'll hear most often is 45 liters per year. It comes from a long-term study of donor plasmapheresis that concluded regular donor plasmapheresis of up to 45 L of plasma per year "appears to be as safe" as more moderate programs, at least for the parameters it examined — cellular and humoral immunity, iron stores, and cardiovascular risk markers.
Here's the problem the centers won't put on a poster. In the United States, the maximum is two donations a week. At a typical 600–800 mL per session, that works out to roughly 62 to 83 liters a year — above the 45-liter line that study marked as safe.
So the "studied safe" number and the "legally allowed" number don't line up. A US donor at the maximum isn't operating inside the evidence that produced the reassurance — they're past its upper bound.
The 18-month IgG kinetics study: a more complicated story
Not every study points the same direction, and it's important to say so plainly. An 18-month kinetics study followed 49 first-time and 50 repeat plasma donors and tracked how circulating IgG changed over time. It found that IgG declined during the early donations in first-time donors, and then stabilized — what the authors describe as a new homeostatic set point, rather than an endless downward slide.
The same study reported that low-IgG donors still mounted a normal antibody response to vaccination, that IgG level wasn't linked to whether donors came back, and that it wasn't linked to more self-reported health problems. The authors concluded that a single low IgG value shouldn't be over-read, and they favor longitudinal monitoring over fixed thresholds.
This is real, and it tempers the alarm — but it doesn't erase the trial. The kinetics study describes a trajectory in a monitored sample; the randomized trial measured clinically meaningful reductions that grew with frequency and took weeks to recover. Together: the body adapts up to a point, but it does so at a lower level, and levels fall faster and recover slower the more often you donate. That's not "nothing," and it's not a reason to panic either.
What "safe for most people" actually means
Notice what "safe" means in each framing. For the center and the industry, it tends to mean "no scary reaction in the chair, no infection, no harm I can see immediately." Measured against that narrow definition, the evidence is genuinely reassuring: the trial reported only mild adverse events, and donation frequency had no effect on psychological distress.
But "safe" measured against biomarker change is a different question, and the answer is less tidy. The same study that found those mild reactions also found protein, IgG and ferritin falling — more at higher frequency, and taking weeks to come back. Widened that way, "safe" becomes a judgment call, not a fact.
The authors of the randomized trial didn't declare the practice dangerous. They concluded the reductions were substantial, that they grew with frequency, and that further research is needed on the long-term health implications. That's the precautionary principle in practice: where there is genuine, unresolved uncertainty and the harm is plausible and affects a very large population of donors, the responsible move is caution, not a green light — especially when many donors do this weekly for years and the long-term, high-frequency, well-nourished trial that would settle it hasn't been run.
Reasonable people can disagree about how seriously to take this. What you shouldn't accept is the claim that the science is settled and everything checks out. It isn't.
Why the deferral data is misleading
The industry has its own defense: "Look at our deferral numbers." The largest analysis of US source-plasma deferrals covers roughly 4.6 million donor-deferral events across 255 centers over three years. Among those deferrals, the single most common reason was unacceptable blood pressure or pulse (about 28%), followed by unacceptable hematocrit (about 14–16%). Deferrals for total protein were a much smaller share — about 4%.
The intended takeaway is obvious: "See, almost nobody fails the protein test, so donors aren't being depleted." That's the misleading part.
The protein test is a single reading at a single moment, gated on what you ate that day. Centers coach donors to load up on protein before donating precisely so they'll pass it — a protein-rich meal a few hours earlier can carry a chronically depleted donor over the line. So a low protein-deferral rate doesn't tell you donors are fine. It tells you the test is easy to pass on the day: a screening gate, not a measure of long-term depletion.
None of this means every frequent donor is damaged. It means the science is real, the "safe" framing is narrower than it sounds, and the industry's own reassurance — the deferral data — measures the wrong thing. If you're going to donate, know what's actually being taken.